Besides, polymorphisms in FCGR2A have been validated with high degree association of trastuzumab and cetuximab benefit in the adjuvant treatment of breast cancer [39] and colorectal cancer [40]. The gene discussed is FCGR2A; the disease is breast carcinoma.